Business Context and Reporting Period
This Form 8-K filing by Curanex Pharmaceuticals Inc (Nasdaq: CURX) reports on events occurring on May 5, 2026. The Company is an emerging growth company incorporated in Nevada, with principal executive offices in Jericho, NY. The filing addresses a critical regulatory matter regarding the Company's continued listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific financial data regarding revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance status related to the Company's stock price.
Material Changes and Events
- Initial Non-Compliance: On November 5, 2025, Nasdaq notified the Company that its common stock closing bid price had been below the required $1.00 per share minimum for 30 consecutive business days.
- First Compliance Period: The Company was granted an initial 180-day compliance period ending May 4, 2026, which it failed to satisfy.
- Extension Granted: On May 5, 2026, Nasdaq granted an additional 180-day compliance period extending until November 2, 2026.
- Basis for Extension: The extension was granted because the Company met all other initial listing requirements, including the market value of publicly held shares, despite the failure to meet the Minimum Bid Price requirement.
Outlook, Management Commentary, and Risks
Management has notified Nasdaq of its intention to cure the deficiency during the second compliance period, potentially by implementing a reverse stock split. The Company is actively monitoring its closing bid price. To regain compliance, the stock must trade at or above $1.00 per share for a minimum of 10 consecutive business days at any time during the extension.
Risks and Contingencies:
- If the Company fails to demonstrate compliance by November 2, 2026, Nasdaq will issue a notification of delisting.
- The Company may appeal a delisting determination to a Nasdaq Hearings Panel.
- There is no assurance that the Company will successfully regain compliance, even if it maintains other listing requirements.
Investor Verification Checklist
- Verify the current closing bid price of CURX stock relative to the $1.00 threshold.
- Monitor for any future announcements regarding the execution of a reverse stock split.
- Track the 10 consecutive business day window required to trigger written confirmation of compliance from Nasdaq.
- Review the Company's cash position to assess its ability to fund operations if delisting occurs or if a reverse split is implemented.